Oxycodone and Sufentanil for Analgesia in Hip Surgery

Analgesia, Patient-Controlled Clinical Trial

Official title:

Comparison of Oxycodone and Sufentanil for Analgesic Efficacy After Hip Surgery: a Prospective, Multicenter Randomized Controlled Trial

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT03685188
• Other study ID #: WCH2018086
• Status: Enrolling by invitation
• Phase: Phase 4
• Start date: December 1, 2018
• Est. completion date: July 31, 2025

Study information

• Verified date: January 2024
• Source: West China Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

We design this randomized controlled trial to compare the safety and efficacy of Oxycodone and Sufentanil for postoperative patient-controlled analgesia in patients undergoing hip surgery, with a view to finding the optimal postoperative analgesic regime with fewer adverse reactions and promoting patients' rehabilitation.

Description:

Hip surgery is a common type of orthopedic surgery. The pathologies are complex, including chronic conditions such as femoral head necrosis, primary hip dysplasia, hip joint osteoarthritis and rheumatoid arthritis, as well as acute diseases such as femoral neck fractures and intertrochanteric fractures. The surgical treatment includes closed reduction and internal fixation, open reduction and internal fixation, hemiarthroplasty (femoral head replacement), and total hip arthroplasty, etc. The population of patients undergoing hip surgery has a high proportion of elderly (>65 years old), with multiple preoperative comorbidities, and significant postoperative pain. We must achieve the balance between the providing sufficient analgesia and minimizing associated adverse reactions perioperatively for such group of patients, therefore promoting patients' rehabilitation.

Sufentanil, a pure μ receptor agonist with active metabolite, is a long-acting strong opioid which has high analgesic efficacy. It is commonly used in anesthesia practice, not only for intraoperative analgesia, but also postoperative pain relief, i.e. a popular drug of choice used for Patient Control Intravenous Analgesia (PCIA). However, sufentanil is associated with high incidence of postoperative nausea and vomiting (PONV), respiratory depression and other adverse reactions, which could negatively affect the patient's analgesic satisfaction, and compromise the course of postoperative recovery. It is important to establish an effective and safe postoperative analgesic regime that can achieve the comparable analgesic efficacy with reduced incidence of adverse reactions. Oxycodone is a semi-synthetic opioid which is extracted from the thebaine, it activates both μ and κ opioid receptors. It has been reported to have good analgesic effect and lower incidence of adverse reactions such as PONV in comparison with Morphine, and could be a reasonable option for PCIA. As Oxycodone can agonize κ receptors and reduce visceral pain, most of the existing studies on Oxycodone are focused on laparoscopic cholecystectomy and other abdominal surgeries, with the average age of study patients is between 40 to 55 years old, and also lack of large sample studies.

Based on the abovementioned literatures, we propose the hypothesis that in hip surgery, compared with Sufentanil PCIA, the equipotency dose of Oxycodone PCIA can achieve the same postoperative analgesic efficacy and may also reduce the incidence of adverse reactions associated with opioids.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 570
• Est. completion date: July 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients undergoing unilateral hip surgery, sign the "informed consent form"

• Age above 18 years old

Exclusion Criteria:

• Pregnant or lactating women

• Patients with history of drug abuse, including but not limited to opioids, amphetamines, ketamine, etc

• Allergic to opioids

• Have history of nervous system diseases such as peripheral neuropathy, or psychiatric mental illness

• Other conditions that the investigators consider unsuitable for participation in the study, such as deaf, Parkinson's disease, and difficult to communication etc

Related Conditions & MeSH terms

• Analgesia, Patient-Controlled

Intervention

Drug:
• Oxycodone Hydrochloride
Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 0.4 mg/ml of oxycodone for postoperative analgesia.
• Sufentanil Citrate
Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 µg/ml of sufentanil for postoperative analgesia.

Locations

Country	Name	City	State
China	West China Hospital, Sichuan University	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of post operative nausea and vomiting (PONV)	The proportion of subjects who experienced PONV	Up to 72 hours after operation
Primary	Postoperative numerical rating scales (NRS) at rest	Resting NRS pain scores at 2 h after surgery.	Up to 72 hours after operation
Secondary	Postoperative NRS on movement	Postoperative NRS pain score on movement, up to 72hr.	Up to 72 hours after operation
Secondary	Postoperative complications	Incidence of postoperative adverse reactions and complications	Up to 30 days after operation
Secondary	Residual amount of drug	Residual amount of drug in the analgesic pump.	Up to 72 hours after operation
Secondary	Length of stay (LOS) in hospital	Time frame from the day of hospital admission to discharge from the hospital (unit: days)	Up to 30 days after operation
Secondary	Postoperative LOS	Time frame from the day of operation to discharge from the hospital (unit: days).	Up to 30 days after operation
Secondary	Re-admission rate	The incidence of re-admission within 30 days after surgery.	Up to 30 days after operation
Secondary	Total in-hospital cost.	Total hospitalization expenses after the destruction of costly consumables in orthopedic operation.	Up to 30 days after operation
Secondary	Time from the end of operation to the first onset of PONV	Time from the end of operation to the first onset of PONV	Up to 30 days after operation
Secondary	The severity of first PONV and the most severe PONV	The severity of PONV is scored from 0 to 10, and 0 represents no PONV at all, and 10 represents very severe PONV.	Up to 30 days after operation
Secondary	Motion of hip joints	Range of motion of hip joints during 3 days after operation.	Up to 72 hours after operation
Secondary	Straight leg raising time	Time from the end of operation to the time that patient can raise his affected lower limb by himself (Unit: hour).	Up to 72 hours after operation
Secondary	Ground exercise time	Time from the end of operation to the time that patient can do the ground exercise by himself (Unit: hour).	Up to 72 hours after operation
Secondary	Mobilization time	Time frame from the end of operation to able to walk without external assistance (Walking aids such as crutches can be used, unit: hour).	Up to 72 hours after operation